Company: ABUS
Filing Date: 2025-12-11
Form Type: 8-K
Source: 0001171843-25-007879
Chunk: 0

Company: Arbutus Biopharma Corp
Filing Date: 2025-12-11
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On December 11, 2025, Lindsay Androski, Chairperson, Chief Executive Officer
and President of Arbutus Biopharma Corporation (the “ Company”) will give a presentation regarding the Company’s ongoing
lawsuits against Moderna Therapeutics, Inc., Pfizer Inc. and BioNTech SE, for their use of the Company’s patented lipid nanoparticle
technology in their COVID-19 vaccines (“ LNP Litigation”), as part of Roivant Sciences Ltd.’s 2025 Investor Day. The
LNP Litigation slides that Ms. Androski will present are filed herewith as Exhibit 99.1 and are incorporated by reference herein.

The LNP Litigation slides contain forward-looking statements within
the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and
forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements).
Forward-looking statements in the LNP Litigation slides include statements about the Company’s plans with respect to the
ongoing patent litigation matters, and the expected timing thereof. With respect to the forward-looking statements contained in the
LNP Litigation slides, the Company has made numerous assumptions regarding the LNP Litigation. While the Company considers these
assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and
social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s
actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements contained therein. Known risk factors include, among others: uncertainties
associated with litigation generally and patent litigation specifically; economic and market conditions may worsen; market shifts
may require a change in strategic focus; and risks related to the sufficiency of the Company’s cash resources for its
foreseeable and unforeseeable operating expenses and capital expenditures.

A more complete discussion of the risks and uncertainties facing the Company
appears in the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s
continuous and periodic disclosure filings, which are available at www. sedar. com and at www. sec. gov. All forward-looking statements in
the LNP Litigation slides are qualified in their entirety by this cautionary statement, and